Brief: Arbutus Says Imdusiran With Short Course Interferon Achieves Sustained Undetectable HBsAg, A Necessity For HBV Functional Cure
05/06/2024 07:31
June 5 (Reuters) - Arbutus Biopharma Corp ABUS.O :
* ARBUTUS’ IMDUSIRAN WITH SHORT COURSE INTERFERON ACHIEVES
SUSTAINED UNDETECTABLE HBSAG, A NECESSITY FOR HBV FUNCTIONAL
CURE
Source text for Eikon: ID:nGNX7K3YLN
Further company coverage: ABUS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arbutus Biopharma
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
Arbutus rises after FDA lifts clinical hold for experimental hepatitis B drug
Brief: Arbutus Announces Final Results Of Its Us$230 Million Modified “Dutch Auction” Tender Offer
Brief: Arbutus Announces Preliminary Results Of Its Us$230 Million Modified “Dutch Auction” Tender Offer
U.S. STOCKS ON THE MOVE-Moderna, O-I Glass, Aveanna Healthcare